Validation of a register-based algorithm for recurrence in rectal cancer by Colov, Emilie Palmgren et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Validation of a register-based algorithm for recurrence in rectal cancer
Colov, Emilie Palmgren; Fransgaard, Tina; Klein, Mads; Gögenur, Ismail
Published in:
Danish Medical Journal
Publication date:
2018
Document version
Publisher's PDF, also known as Version of record
Document license:
Unspecified
Citation for published version (APA):
Colov, E. P., Fransgaard, T., Klein, M., & Gögenur, I. (2018). Validation of a register-based algorithm for
recurrence in rectal cancer. Danish Medical Journal, 65(10), [A5507].
Download date: 03. Feb. 2020
1DANISH MEDICAL JOURNAL
ORIgINAL ARtICLE
Validation of a register-based algorithm  
for recurrence in rectal cancer 
Emilie Palmgren Colov1, Tina Fransgaard2, Mads Klein3 & Ismail Gögenur2
1) Department of 
Surgery,  
Slagelse Hospital
2) Department of 
Surgery, Zealand 
University Hospital
3) Department of 
Surgery, Herlev 
Hospital, Denmark
Dan Med J  
2018;65(10):A5507
Dan Med J 65/10  October 2018 
In most cases, surgery is the preferred treatment for 
colorectal cancer, but 30-40% of potentially curable 
colorectal cancer patients relapse [1]. Death and dis-
ease-free survival are often used as important outcomes 
in cancer research. Advances in the treatment of recur-
rence after colorectal cancer have translated into im-
proved survival in patients with recurrent colorectal 
cancer [2, 3]. This makes recurrence, and not only 
death, an important oncological endpoint within the 
field of cancer research.
Denmark has a long-standing tradition for nation-
wide registers. Unfortunately, recurrence is not cur-
rently recorded systematically in these registers. In  
order to determine the incidence of recurrence after 
surgery for colorectal cancer, an algorithm based on 
the Danish registers was developed [4]. Until now, 
studies focusing on recurrence have been limited to de-
termining if a patient experienced recurrence by re-
viewing the medical records. The cohort used for devel-
oping the algorithm consisted of colorectal cancer 
patients operated and registered in the Danish 
Colorectal Cancer Group’s (DCCG) database between 
May 2001 and December 2011. The findings of the  
algorithm were validated in two different actively fol-
lowed cohorts of colorectal cancer patients in the  
original study [4]. 
The aim of the present study was to validate the 
previously developed algorithm in a nationwide cohort 
of patients with rectal cancer, thereby assessing the ex-
ternal validity of the method. 
METHODS
In Denmark, all persons with a permanent residence 
are registered in the Danish Civil Registration System 
with a unique Central Person Register (CPR) number 
[5]. The CPR number is used whenever a person comes 
into contact with the Danish authorities, including Dan-
ish healthcare. This makes it possible to merge infor-
mation from different registers.
In the present study, data were obtained from the 
following registers: the Danish Civil Registration Sys-
tem, the Danish National Patient Register (NPR) and 
the Danish Pathology Register (DPR).
The NPR contains information about contacts with 
the healthcare system. This includes information about 
diagnoses (using the International Classification of 
Diseases, tenth revision (ICD-10), treatments and pro-
cedures [6]. The DPR records information about all bi-
ological specimens. The specimens are described using 
the Danish version of the Systematized Nomenclature 
of Medicine (SNOMED) codes [7].
To validate the algorithm, a cohort consisting of pa-
tients with rectal cancer operated with curative intent 
between January 2009 and August 2012 was used. This 
cohort was derived from the DCCG’s database which 
contain information on all patients undergoing surgery 
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for colorectal cancer in Denmark. The cohort was de-
scribed in detail in a previous study [8] where the med-
ical records were assessed in order to evaluate compli-
cations, recurrence and survival. In the previous study, 
recurrence was defined as clinical, radiological or path-
ological recurrence described by the clinicians in the 
medical record. In the present study, the incidence of 
recurrence found when using the algorithm was com-
pared with the incidence of recurrence found when as-
sessing the medical records.
According to the algorithm previously described by 
Lash et al [4], recurrence was defined as recurrence 
more than 180 days after colorectal cancer surgery. 
The algorithm was suited only for patients with colo-
rectal cancer who had not had another primary cancer 
(defined as any cancer disease with the exception of 
non-melanoma skin cancer (ICD-10 C44)) prior to their 
diagnosis of colorectal cancer. Furthermore, patients 
who died or were diagnosed with a new primary tu-
mour or metastasis within 180 days after surgery were 
excluded.
The patients were identified as having recurrence if 
at least one of the following four criteria was fulfilled:
1)  A diagnosis code for metastases was found in the 
NPR 180 days or more after surgery without a di-
agnosis of a new primary cancer between surgery 
and the date of the metastasis code.
2)  A cytostatic therapy code 180 days or more after 
surgery. The patient must not have been diagnosed 
with another primary cancer between colorectal 
cancer surgery and the date of the cytostatic ther-
apy code.
3)  The patients had SNOMED combinations describ-
ing metastasis or local recurrence for colorectal 
cancer recorded in the DPR 180 days or more after 
the colorectal cancer surgery without a new pri-
mary cancer in-between.
4)  One of the specific codes for local recurrence of 
colorectal cancer.
A more detailed description of the algorithm can be 
found elsewhere [4]. 
In this study, no information was extracted from the 
Danish Cancer Register even though this formed part of 
the original algorithm. This was chosen because infor-
mation has been transferred directly from the NPR to 
the Cancer Register since 2004. Therefore, the relevant 
data for the years included in this study were retrieved 
directly from the NPR.
Statistics
To examine the concordance between the two meth-
ods, Kappa statistics was used. The performance of the 
algorithm in terms of sensitivity and specificity was es-
timated from the contingency table using results from 
the medical records as the gold standard. Analyses 
were performed using SAS Proprietary Software Ver-
sion 9.4. (SAS Institute Inc., Cary, NC USA). The study 
was approved by the Danish Data Protection Agency 
(2016-41-4745).
Trial registration: not relevant.
RESULTS
A total of 500 patients were available from the de-
scribed cohort; 107 patients were excluded as they ful-
filled the exclusion criteria. Thus, 393 patients were in-
cluded in the validation analysis. For complete data 
about exclusions, see Figure 1. The follow-up time was 
between 18 months and five years depending on when 
the patient was operated. Table 1 lists the number of 
patients with and without recurrence identified by the 
algorithm and by assessing the medical records.
Recurrence was identified in 53 patients by both the 
algorithm and the medical records, whereas 319 pa-
tients were recurrence-free according to both methods. 
The four different criteria all contributed to identifying 
the patients with recurrence. Most patients fulfilled 
more than one criterion with the combination of an 
ICD-10 code for metastasis, a cytostatic therapy code 
and a SNOMED combination being the most frequent 
(23 patients). Some patients only fulfilled one criterion 
(six patients were only identified by a code for metasta-
sis, six by SNOMED combinations only, five by codes 
for chemotherapy and one by the specific codes for lo-
cal recurrence).
FIGURE 1
Cohort from previous study.
N = 500
Death within 180 days (n =4 )
Metastasis before surgery  
(n = 33) and metastasis within 
180 days (n = 27)
Specific code for local  
recurrence within 180 days  
(n = 1)
Cohort included in 
validation analysis
Primary tumour before CRC  
(n = 34), other primary tumour 
within 180 days (n = 8)
N = 496
N = 436
N = 394
N = 393
CRC = colorectal cancer.
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Kappa statistics showed a high level of concordance 
between the algorithm and the medical records with a 
Kappa value (95% confidence interval) of 0.80 (0.72-
0.88). The sensitivity and specificity of the algorithm 
were 88% (77-95%) and 96% (93-98%), respectively.
In seven cases, recurrence was identified through 
the medical records but was not identified by the al-
gorithm. Furthermore, 14 recurrences were identified 
by the algorithm but not found in the medical records.
Six patients were identified in the medical records 
as having recurrent or metastatic disease within the 
first 180 days but were not excluded by the algorithm. 
In two of these cases, recurrence was, however, iden-
tified after the 180 days by the algorithm.
DISCUSSION
The study showed good concordance between the inci-
dence of recurrence found by the algorithm and that of 
the medical records review.
The results were similar to those from the study de-
scribing the algorithm. In that study, a sensitivity of 
95% and a specificity of 97% were found when validat-
ing the algorithm [4].
Some discrepancies between the algorithm and the 
medical records were found. The algorithm identified 
14 cases of recurrence that were not identified by the 
medical records, and the medical records identified 
seven cases of recurrence that were not identified by 
the algorithm.
It was possible to find an explanation for some of 
the 14 recurrences missing from the medical records by 
reviewing the information from the previous study [8]. 
Three of these patients were described in the medical 
records as having metastatic disease before the opera-
tion. Thus, the clinicians responsible for the registra-
tions at the time of surgery may have wrongly regis-
tered these patients as not having metastatic disease. In 
one patient, a metastasis to the skin was suspected, but 
this was never confirmed in the medical record. One 
could argue that it is a matter of interpretation if this 
should have been recorded as a recurrence when going 
through the medical records. Finally, in one patient, a 
liver metastasis was suspected at first in the medical re-
cord, but subsequently the patient was diagnosed with 
cholangiocarcinoma. This patient was grouped as hav-
ing recurrent rectal cancer by the algorithm because 
the ICD-10 code for metastasis was dated two weeks 
before the ICD-10 code for cholangiocarcinoma.
The seven cases of recurrence that were identified 
by the medical records but not by the algorithm may 
have been missed by the algorithm due to insufficient 
coding of the clinical findings.
In the present study, medical records were used as 
the gold standard since this has so far been the method 
used to identify recurrences after colorectal cancer.  
All information on the patients from the national elec-
tronic medical record was examined. This national 
electronic medical record should contain the same in-
formation as the local medical records at each hospital 
since information from the local records is automat-
ically uploaded to the national record.
Using the algorithm has several major strengths. 
Using the algorithm makes it is possible to determine 
recurrence and disease-free survival for larger groups 
of patients. So far, it has been possible to determine the 
incidence of recurrence only by reviewing the patients’ 
medical records. This is time consuming and limits the 
possible sample size. With the algorithm, it will be pos-
sible to perform large register-based studies with recur-
rence and disease-free survival as primary outcomes, 
making it possible to assess the effect of changes in var-
ious treatment methods. This is valuable, especially in 
the light of the fact that more patients survive recurrent 
colorectal cancer for longer periods of time [2, 3]. The 
algorithm integrates information from various sources, 
which increases the chances of identifying recurrence 
even if it has not been identified correctly in one of the 
registers.
The algorithm also has some design limitations. All 
patients diagnosed with another cancer before colorec-
tal cancer surgery, except non-melanoma skin cancer, 
are excluded from the algorithm. This is done because 
in the registers the diagnosis codes for metastases do 
not specify which primary cancer caused the meta-
stasis. As survival after other types of cancer also im-
proves, this may prove a challenge in the future. In ad-
dition, patients with metastatic disease at the time of 
surgery or within 180 days after surgery are excluded 
even if this metastasis has successfully been removed 
and the patient clinically is considered disease free.  
It is still possible that a patient was clinically or radio-
logically diagnosed with a metastasis but that no biopsy 
was taken, and no treatment was initiated. If the clin-
ician mistakenly did not register an ICD-10 code for 
metastasis, it would not be identified through the  
al gorithm. Also, the algorithm does not distinguish  
between local recurrence and distant metastasis. 
Especially when examining results after rectal cancer 
surgery, this would have been an advantage. 
TABLE 1
Recurrence of rectal cancer identified by the algorithm and by the medical 
records. The values are n (%).
Medical record
Algorithm recurrence no recurrence total
Recurrence 53  14  67 (17.0)
No recurrence  7 319 326 (83.0)
Total 60 (15.3) 333 (84.7) 393 (100)
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When using the algorithm, recurrence was defined 
as metastatic disease or local recurrence after the first 
180 days postoperatively. The 180-day limit was cho-
sen arbitrarily. This was done because metastases diag-
nosed within the first 180 days may represent meta-
stases already present at the time of surgery, but which 
had not been diagnosed at that time. In the former 
study, this time limit was not used, and six patients 
were identified as having recurrent disease within the 
first 180 days. These patients ought to have been ex-
cluded by the algorithm. Two of them were identified 
by the algorithm as having recurrent disease after the 
first 180 days. It is to be expected that time of recur-
rence will be somewhat later when identified by the al-
gorithm than when going through the medical records. 
Clinical or radiological signs of recurrence are usually 
mentioned in the medical records before the actual reg-
istration of the diagnosis code is done.
The primary strength of this validation study lies in 
the completeness of access to medical records for the 
500 rectal cancer patients from all regions of Denmark. 
In this manner, it was possible to compare recurrences 
as they have been determined until now with this new 
algorithm.
A limitation of the study was that the purpose of re-
viewing the medical records in the first place was not to 
validate the algorithm. The decision to validate the al-
gorithm was made after the data extraction for the for-
mer study [8] was finished. Although the primary study 
was performed to identify recurrences, one problem 
was that when assessing the medical records, it was not 
explored if the patient had had another primary tu-
mour before his or her colorectal cancer. Ideally, this 
information would have been available. If this informa-
tion had been available, it would have been possible to 
exclude these patients from the medical record cohort 
separately and then subsequently compare the two 
groups. Without this information, it was necessary to 
use only the algorithm to exclude all patients with a 
primary tumour before colorectal cancer surgery and 
within the first 180 days.
CONCLUSIONS
The algorithm was found to be suitable and effective in 
identifying patients with and without recurrence after 
surgery for rectal cancer. Using this algorithm makes it 
possible to use recurrence and disease-free survival as 
endpoints in large register-based studies. Further stud-
ies should aim to modify the algorithm so that it may 
also be used in studies of other types of cancer and to 
distinguish between local recurrences and distant  
metastases.
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